Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint

Sorafenib is a multikinase inhibitor approved as the first line treatment for late stage hepatocellular carcinoma (HCC). Due to its significant variation in clinical benefits among patients, defining prognostic biomarkers for sorafenib sensitivity in HCC would allow targeted treatment. Phosphorylate...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jiang, Ji, Tong, Zhao, Jie, Li, Gaofeng, Zhang, Jian, Jin, Renan, Liu, Jinghua, Liu, Xiaolong, Liang, Xiao, Huang, Diyu, Xie, Anyong, Lin, Hui, Cang, Yong, Cai, Xiujun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5173058/
https://www.ncbi.nlm.nih.gov/pubmed/27129180
http://dx.doi.org/10.18632/oncotarget.8978

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5173058/
https://www.ncbi.nlm.nih.gov/pubmed/27129180
http://dx.doi.org/10.18632/oncotarget.8978

Ejemplares similares